{"entity":{"id":"nct06064877","kind":"trial","name":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma","aka":["FIERCE-HN"],"tldr":"A phase 3 trial testing Ficlatuzumab in head and neck squamous cell carcinoma, now recruiting.","summary":"A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06064877, led by AVEO Pharmaceuticals, and recruiting on the registry. Official title: A Multicenter, Randomised, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN). Planned enrolment is 410 participants (estimated). The study started in 2024-01-11 and primary completion is expected in 2027-08. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT06064877","url":"https://clinicaltrials.gov/study/NCT06064877"}],"tags":["ctgov-ingest"],"related":[],"cancers":["head-and-neck","hpv-negative-head-and-neck-cancer","recurrent-metastatic-hnscc"],"sections":[],"technologies":[],"targets":[],"drugs":["ficlatuzumab"],"companies":["aveo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06064877","phase":"3","setting":"A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)","sponsor":"AVEO Pharmaceuticals","started":"2024-01-11","startedType":"actual","enrolled":410,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06064877/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hpv-negative-head-and-neck-cancer","kind":"cancer","name":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","route":"/cancers/hpv-negative-head-and-neck-cancer/"},{"id":"recurrent-metastatic-hnscc","kind":"cancer","name":"Recurrent or metastatic head and neck squamous cell carcinoma","route":"/cancers/recurrent-metastatic-hnscc/"}],"drug":[{"id":"ficlatuzumab","kind":"drug","name":"Ficlatuzumab","route":"/drugs/ficlatuzumab/"}],"company":[{"id":"aveo","kind":"company","name":"AVEO Oncology (LG Chem)","route":"/companies/aveo/"}]}}